TR201902533T4 - Antibiyotiklerin kullanımı ile bağdaştırılan hastalıkların tedavisi. - Google Patents
Antibiyotiklerin kullanımı ile bağdaştırılan hastalıkların tedavisi. Download PDFInfo
- Publication number
- TR201902533T4 TR201902533T4 TR2019/02533T TR201902533T TR201902533T4 TR 201902533 T4 TR201902533 T4 TR 201902533T4 TR 2019/02533 T TR2019/02533 T TR 2019/02533T TR 201902533 T TR201902533 T TR 201902533T TR 201902533 T4 TR201902533 T4 TR 201902533T4
- Authority
- TR
- Turkey
- Prior art keywords
- antibiotics
- treatment
- compound
- diseases associated
- resistant
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000003242 anti bacterial agent Substances 0.000 title 1
- 229940088710 antibiotic agent Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 241000193163 Clostridioides difficile Species 0.000 abstract 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 abstract 1
- 241000191967 Staphylococcus aureus Species 0.000 abstract 1
- 108010059993 Vancomycin Proteins 0.000 abstract 1
- 229960003085 meticillin Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 abstract 1
- 229960003165 vancomycin Drugs 0.000 abstract 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
Abstract
Buluş, formüle (II) sahip bir bileşik, bileşiği içeren farmasötik bir bileşim ve Clostridium difficile, metisilin dirençli Staphylococcus aureus (MRSA) veya vankomisin dirençli enterok (VRE) varlığından kaynaklanan bir hastadaki bir hastalığın tedavi edilmesi veya önlenmesinde kullanıma yönelik bileşik ile ilgilidir.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57069704P | 2004-05-14 | 2004-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201902533T4 true TR201902533T4 (tr) | 2019-03-21 |
Family
ID=35428857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/02533T TR201902533T4 (tr) | 2004-05-14 | 2005-05-13 | Antibiyotiklerin kullanımı ile bağdaştırılan hastalıkların tedavisi. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20070173462A1 (tr) |
| EP (4) | EP1765312B1 (tr) |
| JP (2) | JP5734545B2 (tr) |
| AT (1) | ATE516024T1 (tr) |
| BR (1) | BRPI0511119A (tr) |
| CA (2) | CA2776682A1 (tr) |
| CY (2) | CY1117501T1 (tr) |
| DK (3) | DK2305244T3 (tr) |
| ES (4) | ES2608046T3 (tr) |
| HU (3) | HUE043945T2 (tr) |
| LT (1) | LT2305245T (tr) |
| MX (2) | MX344601B (tr) |
| PL (3) | PL2070530T3 (tr) |
| PT (2) | PT2305245T (tr) |
| SI (2) | SI2070530T1 (tr) |
| TR (1) | TR201902533T4 (tr) |
| WO (1) | WO2005112990A2 (tr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7906489B2 (en) * | 2004-05-14 | 2011-03-15 | Optimer Pharmaceuticals, Inc. | 18-membered macrocycles and analogs thereof |
| US7378508B2 (en) * | 2007-01-22 | 2008-05-27 | Optimer Pharmaceuticals, Inc. | Polymorphic crystalline forms of tiacumicin B |
| MX2007009196A (es) * | 2005-01-31 | 2009-02-25 | Optimer Pharmaceuticals Inc | Compuestos macrocilicos de 18 miembros y analogos de los mismos. |
| CA2626698C (en) * | 2005-10-21 | 2015-12-01 | Optimer Pharmaceuticals, Inc. | Method of treating clostridium difficile-associated diarrhea |
| TWI523654B (zh) * | 2007-11-27 | 2016-03-01 | 默沙東藥廠 | 抗生素巨環化合物以及其製造及使用之方法 |
| WO2009117310A2 (en) * | 2008-03-17 | 2009-09-24 | Cedars-Sinai Medical Center | Methods for treatment and prevention of mrsa/mssa |
| WO2011044208A1 (en) * | 2009-10-06 | 2011-04-14 | Scott Dorfner | Antibiotic formulations providing reduced gastrointentestinal side effects |
| US20120225889A1 (en) * | 2009-11-17 | 2012-09-06 | Piramal Life Sciences Limited | Use of macrocyclic lactone derivatives for the treatment of inflammatory disorders |
| US9138441B2 (en) | 2009-12-31 | 2015-09-22 | Ira Milton Trachtman | Compositions and method for treatment and prophylaxis of inflammatory bowel disease |
| MX2012013374A (es) * | 2010-05-18 | 2013-05-06 | Optimer Pharmaceuticals Inc | Tratamiento de infecciones de clostridium difficile en pacientes bajo terapia con antibioticos. |
| JO3464B1 (ar) | 2013-01-15 | 2020-07-05 | Astellas Pharma Europe Ltd | التركيبات الخاصة بمركبات التياكوميسين |
| UA122203C2 (uk) | 2014-05-09 | 2020-10-12 | Астеллас Фарма Юроп Лтд | Схема лікування із застосуванням сполуки тіакуміцину |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3279995A (en) | 1963-05-31 | 1966-10-18 | Allen F Reid | Shaped pellets |
| GB1458512A (en) * | 1973-11-22 | 1976-12-15 | Lepetit Spa | Antibiotic substance |
| US4111202A (en) | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for the controlled and delivery of agent over time |
| US4918174A (en) | 1986-09-26 | 1990-04-17 | Abbott Laboratories | Tiacumicin compounds |
| US4786503A (en) | 1987-04-06 | 1988-11-22 | Alza Corporation | Dosage form comprising parallel lamine |
| US5443841A (en) | 1992-06-15 | 1995-08-22 | Emisphere Technologies, Inc. | Proteinoid microspheres and methods for preparation and use thereof |
| US6235313B1 (en) | 1992-04-24 | 2001-05-22 | Brown University Research Foundation | Bioadhesive microspheres and their use as drug delivery and imaging systems |
| US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
| US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| US5583115A (en) * | 1995-05-09 | 1996-12-10 | Abbott Laboratories | Dialkyltiacumicin compounds |
| US6143211A (en) | 1995-07-21 | 2000-11-07 | Brown University Foundation | Process for preparing microparticles through phase inversion phenomena |
| US5767096A (en) * | 1996-07-12 | 1998-06-16 | Abbott Laboratories | Bromotiacumicin compounds |
| IN186245B (tr) | 1997-09-19 | 2001-07-14 | Ranbaxy Lab Ltd | |
| MXPA04009418A (es) * | 2002-03-29 | 2005-06-08 | Schering Corp | Anticuerpos monoclonales humanos par interleucina-5, y metodos y composiciones que comprenden los mismos. |
| US20070105791A1 (en) * | 2002-07-29 | 2007-05-10 | Optimer Pharmaceuticals, Inc. | Method of treating clostridium difficile-associated diarrhea |
| US7507564B2 (en) | 2002-07-29 | 2009-03-24 | Optimer Pharmaceuticals, Inc. | Tiacumicin production |
| US7906489B2 (en) * | 2004-05-14 | 2011-03-15 | Optimer Pharmaceuticals, Inc. | 18-membered macrocycles and analogs thereof |
| US7378508B2 (en) * | 2007-01-22 | 2008-05-27 | Optimer Pharmaceuticals, Inc. | Polymorphic crystalline forms of tiacumicin B |
| ZA200905337B (en) * | 2007-01-22 | 2010-10-27 | Optimer Pharmaceuticals Inc | Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
| TWI523654B (zh) * | 2007-11-27 | 2016-03-01 | 默沙東藥廠 | 抗生素巨環化合物以及其製造及使用之方法 |
-
2005
- 2005-05-13 SI SI200532054A patent/SI2070530T1/sl unknown
- 2005-05-13 PT PT10075450T patent/PT2305245T/pt unknown
- 2005-05-13 HU HUE10075450A patent/HUE043945T2/hu unknown
- 2005-05-13 US US11/596,340 patent/US20070173462A1/en not_active Abandoned
- 2005-05-13 CA CA2776682A patent/CA2776682A1/en not_active Withdrawn
- 2005-05-13 MX MX2014003990A patent/MX344601B/es unknown
- 2005-05-13 HU HUE10075449A patent/HUE031581T2/en unknown
- 2005-05-13 EP EP05748007A patent/EP1765312B1/en active Active
- 2005-05-13 DK DK10075449.8T patent/DK2305244T3/en active
- 2005-05-13 ES ES10075449.8T patent/ES2608046T3/es active Active
- 2005-05-13 SI SI200532245T patent/SI2305245T1/sl unknown
- 2005-05-13 CA CA2566687A patent/CA2566687C/en active Active
- 2005-05-13 DK DK10075450.6T patent/DK2305245T3/en active
- 2005-05-13 DK DK09156339.5T patent/DK2070530T3/da active
- 2005-05-13 MX MXPA06013245A patent/MXPA06013245A/es active IP Right Grant
- 2005-05-13 PL PL09156339T patent/PL2070530T3/pl unknown
- 2005-05-13 ES ES05748007T patent/ES2395404T3/es active Active
- 2005-05-13 JP JP2007513392A patent/JP5734545B2/ja active Active
- 2005-05-13 TR TR2019/02533T patent/TR201902533T4/tr unknown
- 2005-05-13 ES ES10075450T patent/ES2713954T3/es active Active
- 2005-05-13 BR BRPI0511119-6A patent/BRPI0511119A/pt not_active IP Right Cessation
- 2005-05-13 EP EP09156339.5A patent/EP2070530B1/en active Active
- 2005-05-13 WO PCT/US2005/016750 patent/WO2005112990A2/en active Application Filing
- 2005-05-13 HU HUE09156339A patent/HUE027757T2/en unknown
- 2005-05-13 LT LTEP10075450.6T patent/LT2305245T/lt unknown
- 2005-05-13 PT PT100754498T patent/PT2305244T/pt unknown
- 2005-05-13 AT AT05748007T patent/ATE516024T1/de not_active IP Right Cessation
- 2005-05-13 ES ES09156339.5T patent/ES2565609T3/es active Active
- 2005-05-13 PL PL10075449T patent/PL2305244T3/pl unknown
- 2005-05-13 EP EP10075449.8A patent/EP2305244B1/en active Active
- 2005-05-13 PL PL10075450T patent/PL2305245T3/pl unknown
- 2005-05-13 EP EP10075450.6A patent/EP2305245B1/en active Active
-
2012
- 2012-04-26 US US13/457,216 patent/US20130274175A1/en not_active Abandoned
- 2012-06-19 JP JP2012138170A patent/JP6101010B2/ja active Active
-
2016
- 2016-05-13 CY CY20161100404T patent/CY1117501T1/el unknown
-
2019
- 2019-02-28 CY CY20191100248T patent/CY1121284T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121284T1 (el) | Θεραπεια ασθενειων που συνδυαζονται με τη χρηση αντιβιοτικων | |
| NZ597046A (en) | Use of alpha-toxin for treating and preventing staphylococcus infections | |
| ECSP10010042A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119 | |
| GT200600114A (es) | Derivados de ciclopropanocarboxamida | |
| BRPI0606690A2 (pt) | composto; uso do composto para o tratamento de uma doença ou distúrbio associado com uma atividade excessiva de bace; e composição farmacêutica | |
| BRPI0619153B8 (pt) | derivados de 4-amino-pirroltriazina substituída, e composição farmacêutica | |
| EA200900136A1 (ru) | Пирролопиримидины для фармацевтических композиций | |
| DOP2006000268A (es) | Agentes antibacterianos | |
| CY1108196T1 (el) | Αντιμικροβιακες φαρμακευτικες συνθεσεις χορηγουμενες απο το στομα | |
| BRPI0615614A2 (pt) | compostos orgánicos | |
| BRPI0607723A2 (pt) | isotiazoloquinolonas e compostos relacionados como agentes antiinfecciosos | |
| GT200500308A (es) | Nonadepsipeptidos acilados ii | |
| ATE427315T1 (de) | Neue makrolide | |
| ECSP045397A (es) | 6-ALQUILIDEN-PENEMS BICÍCLICOS COMO INHIBIDORES DE LAS b-LACTAMASAS | |
| ATE475408T1 (de) | Formulierungen von tipifarnib zur intravenösen verabreichung | |
| GT200700105A (es) | Inhibidor del factor xa | |
| BR0312211A (pt) | difluortioacetamidas de oxazolidinonas como agentes antibacterianos | |
| ECSP077220A (es) | Tratamiento de infecciones bacterianas | |
| ECSP045405A (es) | Penems 6-alquiliden heterotriciclil como inhibidores de la beta lactamasa | |
| ECSP088132A (es) | INHIBIDORES DE 6-ALQUILIDENO-PENEME B-LACTAMASA BICÍCLICOS Y COMBINACIÓN ANTIBIÓTICA DE ß-LACTAMA: UN ANTIBIÓTICO DE AMPLIO ESPECTRO | |
| NZ594945A (en) | Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof | |
| EA200801023A1 (ru) | Применение фенофибрата или его производного для предотвращения диабетической ретинопатии | |
| PE20080774A1 (es) | Composicion inmunogenica que comprende pnag de estafilococos conjugada con una proteina portadora y polisacarido u oligosacarido capsular de s. aureus | |
| GT200600132A (es) | Una oxindoloxazolidinona como agente antibacteriano | |
| ATE473737T1 (de) | Verwendung von 2,3-dehydronaringenin-derivaten zur behandlung von entzündungsprozessen und diese derivate enthaltende pharmazeutische zusammensetzung |